期刊文献+

拉米夫定停药后慢性乙型肝炎复发的临床特点 被引量:2

下载PDF
导出
摘要 目的研究拉米夫定停药后慢性乙型肝炎复发病例的临床特点。方法回顾拉米夫定疗程、疗效、停药原因及用药前、停药时和复发后的患者病情,生化指标、病毒学指标及YMDD变异情况及预后。结果36例停药患者,其中19.6%疗程不足52周;停药时94.6%HBVDNA转阴者复发时均阳转,5.4%未转阴者复发时HBVDNA上升超过2个对数级;75%(27/36)患者自行停药;医生指导停药的患者中55.6%(5/9)未随访。55.5%(20/36)复发时病情较用药前加重,其YMDD变异率为78.8%(x2=23.23,P<0.01),高于未加重者;复发时间的中位数为12周。结论大部分患者没有按照我国拉米夫定临床应用专家共识指导用药和停药,复发主要是由于HBV再度活跃复制引起肝脏炎症所致;YMDD变异可能是复发时肝损害加重的因素之一。
出处 《实用肝脏病杂志》 CAS 2006年第5期290-291,共2页 Journal of Practical Hepatology
  • 相关文献

参考文献6

二级参考文献30

  • 1[1]Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitsB virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation[J]. Antivir Ther, 1999,4(1):7
  • 2[2]Ben Ari Z, Zemel R, Kazetsker A, et al. Efficacy of lamivudine in patients with hepatitis B virus precoremutant infection before and after liver transplantation [J].Am J Gastroenterol, 1999,94(3):663
  • 3[3]Dienstag JL,Schiff ER,Mitchell M,et al. Extended lamivudine retreatment for chronic hepatitis B:maintenance of viral suppression after discontinuation oftherapy[J]. Hepatology 1999,30(4): 1082
  • 4[4]Ben Ari Z,Pappo O,Zemel R,et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepaticfibrosis[J].Transplan tation, 1999,68(2):232
  • 5[5]Bessesen M,Ives D,Condreay L,et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine[J]. Clin Infect Dis, 1999,28(5):1032
  • 6[6]Peters MG,Singer G,Howard T,et al. Fulminant hepatic failure resulting form lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivosil and hepatitis B immune globulin[J].Transplantation, 1999,68(12):1912
  • 7Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 8Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 9Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 10Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265

共引文献14174

同被引文献7

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部